|
CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4943533A
(en)
|
1984-03-01 |
1990-07-24 |
The Regents Of The University Of California |
Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
EP0368684B2
(en)
|
1988-11-11 |
2004-09-29 |
Medical Research Council |
Cloning immunoglobulin variable domain sequences.
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
EP0491007B1
(en)
|
1989-09-08 |
1996-03-13 |
The Johns Hopkins University |
Structural alterations of the egf receptor gene in human gliomas
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
WO1996033735A1
(en)
|
1995-04-27 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
DE69120146T2
(de)
|
1990-01-12 |
1996-12-12 |
Cell Genesys Inc |
Erzeugung xenogener antikörper
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
ATE158021T1
(de)
|
1990-08-29 |
1997-09-15 |
Genpharm Int |
Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
CA2095633C
(en)
|
1990-12-03 |
2003-02-04 |
Lisa J. Garrard |
Enrichment method for variant proteins with altered binding properties
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
US7018809B1
(en)
|
1991-09-19 |
2006-03-28 |
Genentech, Inc. |
Expression of functional antibody fragments
|
|
FI941572A7
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
|
|
ATE207080T1
(de)
|
1991-11-25 |
2001-11-15 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
|
GB9300059D0
(en)
|
1992-01-20 |
1993-03-03 |
Zeneca Ltd |
Quinazoline derivatives
|
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
|
DK0752248T3
(da)
|
1992-11-13 |
2000-11-13 |
Idec Pharma Corp |
Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
GB9314893D0
(en)
|
1993-07-19 |
1993-09-01 |
Zeneca Ltd |
Quinazoline derivatives
|
|
DE69428764T2
(de)
|
1993-12-24 |
2002-06-20 |
Merck Patent Gmbh |
Immunokonjugate
|
|
US5654307A
(en)
|
1994-01-25 |
1997-08-05 |
Warner-Lambert Company |
Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
|
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
WO1996003397A1
(en)
|
1994-07-21 |
1996-02-08 |
Akzo Nobel N.V. |
Cyclic ketone peroxide formulations
|
|
US5804396A
(en)
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
DE69536015D1
(de)
|
1995-03-30 |
2009-12-10 |
Pfizer Prod Inc |
Chinazolinone Derivate
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
WO1996034096A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
|
JPH11507535A
(ja)
|
1995-06-07 |
1999-07-06 |
イムクローン システムズ インコーポレイテッド |
腫瘍の成長を抑制する抗体および抗体フラグメント類
|
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
SI9620103A
(sl)
|
1995-07-06 |
1998-10-31 |
Novartis Ag |
Pirolopirimidini in postopki za njihovo pripravo
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
|
EA001595B1
(ru)
|
1996-04-12 |
2001-06-25 |
Варнер-Ламберт Компани |
Необратимые ингибиторы тирозинкиназ
|
|
AR007857A1
(es)
|
1996-07-13 |
1999-11-24 |
Glaxo Group Ltd |
Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
|
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
|
CA2722378C
(en)
|
1996-12-03 |
2015-02-03 |
Amgen Fremont Inc. |
Human antibodies that bind tnf.alpha.
|
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
|
US6002008A
(en)
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
|
WO1998050038A1
(en)
|
1997-05-06 |
1998-11-12 |
American Cyanamid Company |
Use of quinazoline compounds for the treatment of polycystic kidney disease
|
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
ES2244066T3
(es)
|
1997-06-24 |
2005-12-01 |
Genentech, Inc. |
Procedimiento y composiciones de glicoproteinas galactosiladas.
|
|
ZA986729B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitors of tyrosine kinases
|
|
ZA986732B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
|
TW436485B
(en)
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
|
AU759779B2
(en)
|
1997-10-31 |
2003-05-01 |
Genentech Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
|
BR9814116A
(pt)
|
1997-11-06 |
2000-10-03 |
American Cyanamid Co |
Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico
|
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
|
DK1034298T3
(da)
|
1997-12-05 |
2012-01-30 |
Scripps Research Inst |
Humanisering af murint antistof
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
|
EA003786B1
(ru)
|
1998-11-19 |
2003-10-30 |
Варнер Ламберт Компани |
N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
CA2704600C
(en)
|
1999-04-09 |
2016-10-25 |
Kyowa Kirin Co., Ltd. |
A method for producing antibodies with increased adcc activity
|
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
|
ES2248127T3
(es)
|
1999-10-04 |
2006-03-16 |
Medicago Inc. |
Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
|
|
EP1229125A4
(en)
|
1999-10-19 |
2005-06-01 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PREPARING A POLYPEPTIDE
|
|
EP1240319A1
(en)
|
1999-12-15 |
2002-09-18 |
Genentech, Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
|
AU767394C
(en)
|
1999-12-29 |
2005-04-21 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
|
CA2953239A1
(en)
|
2000-10-06 |
2002-04-18 |
Kyowa Hakko Kirin Co., Ltd. |
Antibody composition-producing cell
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
CA2430013C
(en)
|
2000-11-30 |
2011-11-22 |
Medarex, Inc. |
Transgenic transchromosomal rodents for making human antibodies
|
|
NZ571596A
(en)
|
2001-08-03 |
2010-11-26 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
CA2463879C
(en)
|
2001-10-25 |
2012-12-04 |
Genentech, Inc. |
Glycoprotein compositions
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
EP1478494B1
(en)
|
2002-02-26 |
2005-10-12 |
Advanced Micro Devices, Inc. |
Method and system for controlling the chemical mechanical polishing of substrates by calculating an overpolishing time and/or a polishing time of a final polishing step
|
|
CA2481658A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Method of enhancing of binding activity of antibody composition to fcy receptor iiia
|
|
EP1500400A4
(en)
|
2002-04-09 |
2006-10-11 |
Kyowa Hakko Kogyo Kk |
MEDICAMENT WITH ANTIBODY COMPOSITION
|
|
BR0309145A
(pt)
|
2002-04-09 |
2005-02-01 |
Kyowa Hakko Kogyo Kk |
Células das quais o genoma é modificado
|
|
ATE503829T1
(de)
|
2002-04-09 |
2011-04-15 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
|
CA2481925A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Therapeutic agent for patients having human fc.gamma.riiia
|
|
EP1498490A4
(en)
|
2002-04-09 |
2006-11-29 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PREPARING ANTIBODY COMPOSITION
|
|
CA2488441C
(en)
|
2002-06-03 |
2015-01-27 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
EP1578373A4
(en)
|
2002-09-11 |
2007-10-24 |
Genentech Inc |
NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM
|
|
JP5401001B2
(ja)
|
2002-09-11 |
2014-01-29 |
ジェネンテック， インコーポレイテッド |
免疫関連疾患の治療のための新規組成物と方法
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
TWI335821B
(en)
|
2002-12-16 |
2011-01-11 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
|
WO2004065416A2
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
JPWO2005035586A1
(ja)
|
2003-10-08 |
2007-11-22 |
協和醗酵工業株式会社 |
融合蛋白質組成物
|
|
JPWO2005035778A1
(ja)
|
2003-10-09 |
2006-12-21 |
協和醗酵工業株式会社 |
α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
|
|
US9296820B2
(en)
|
2003-11-05 |
2016-03-29 |
Roche Glycart Ag |
Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
|
|
EP2478912B1
(en)
|
2003-11-06 |
2016-08-31 |
Seattle Genetics, Inc. |
Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
|
|
WO2005053742A1
(ja)
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
抗体組成物を含有する医薬
|
|
EP1740615B1
(en)
|
2004-03-31 |
2014-11-05 |
Genentech, Inc. |
Humanized anti-tgf-beta antibodies
|
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
|
PT1737891E
(pt)
|
2004-04-13 |
2013-04-16 |
Hoffmann La Roche |
Anticorpos anti p-selectina
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
DK1791565T3
(en)
|
2004-09-23 |
2016-08-01 |
Genentech Inc |
Cysteingensplejsede antibodies and conjugates
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
EP1891107B1
(en)
|
2005-05-12 |
2011-07-06 |
ZymoGenetics, Inc. |
Compositions and methods for modulating immune responses
|
|
US8219149B2
(en)
|
2005-06-29 |
2012-07-10 |
Nokia Corporation |
Mobile communication terminal
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
ES2577292T3
(es)
|
2005-11-07 |
2016-07-14 |
Genentech, Inc. |
Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
|
|
EP1973951A2
(en)
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
|
TW200812616A
(en)
|
2006-05-09 |
2008-03-16 |
Genentech Inc |
Binding polypeptides with optimized scaffolds
|
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
|
SG10202112838YA
(en)
|
2008-04-09 |
2021-12-30 |
Genentech Inc |
Novel compositions and methods for the treatment of immune related diseases
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
MX2011009413A
(es)
*
|
2009-03-11 |
2011-10-21 |
Ambit Biosciences Corp |
Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
|
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
|
ES2692268T5
(en)
|
2011-03-29 |
2025-02-26 |
Roche Glycart Ag |
Antibody fc variants
|
|
BR112016000853A2
(pt)
|
2013-07-16 |
2017-12-12 |
Genentech Inc |
métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit
|
|
EP3119913B1
(en)
|
2014-03-21 |
2021-01-06 |
The Brigham and Women's Hospital, Inc. |
Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
|
|
EP3169363A4
(en)
|
2014-07-16 |
2018-02-21 |
F. Hoffmann-La Roche AG |
Methods of treating cancer using tigit inhibitors and anti-cancer agents
|
|
MD4733C1
(ro)
|
2014-08-19 |
2021-07-31 |
Merck Sharp & Dohme Corp |
Anticorpi anti-TIGIT
|
|
JP6180663B2
(ja)
|
2014-12-23 |
2017-08-16 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｔｉｇｉｔに対する抗体
|
|
JP2018503373A
(ja)
|
2014-12-30 |
2018-02-08 |
ジェネンテック， インコーポレイテッド |
がんの予後診断及び治療のための方法及び組成物
|
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
|
CN108290936B
(zh)
|
2015-08-14 |
2022-07-12 |
默沙东公司 |
抗tigit抗体
|
|
EP3344658B1
(en)
|
2015-09-02 |
2022-05-11 |
Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. |
Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
|
|
EP3349792A1
(en)
|
2015-09-14 |
2018-07-25 |
Compass Therapeutics LLC |
Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-
|
|
PE20181046A1
(es)
|
2015-09-25 |
2018-07-03 |
Genentech Inc |
Anticuerpos anti-tigit y metodos de uso
|
|
US10537633B2
(en)
|
2016-03-04 |
2020-01-21 |
Jn Biosciences Llc |
Antibodies to TIGIT
|
|
US12297266B2
(en)
|
2016-04-18 |
2025-05-13 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human CD40 and uses thereof
|
|
SG11201809336QA
(en)
|
2016-05-09 |
2018-11-29 |
Igm Biosciences Inc |
Anti-pd-l1 antibodies
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
WO2018022946A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
IL317989A
(en)
|
2016-08-17 |
2025-02-01 |
Compugen Ltd |
Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
|
|
WO2018047139A1
(en)
|
2016-09-12 |
2018-03-15 |
Aurigene Discovery Technologies Limited |
Compounds as modulators of tigit signalling pathway
|
|
MX2019006072A
(es)
|
2016-11-30 |
2019-08-14 |
Oncomed Pharm Inc |
Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
|
|
WO2018102746A1
(en)
|
2016-12-02 |
2018-06-07 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to tigit
|
|
WO2018128939A1
(en)
|
2017-01-05 |
2018-07-12 |
Gensun Biopharma Inc. |
Checkpoint regulator antagonists
|
|
AU2018206481B2
(en)
*
|
2017-01-09 |
2025-02-27 |
Tesaro, Inc. |
Methods of treating cancer with anti-PD-1 antibodies
|
|
US20190367579A1
(en)
|
2017-02-27 |
2019-12-05 |
Shattuck Labs, Inc. |
Tigit- and light-based chimeric proteins
|
|
EP3589313A4
(en)
|
2017-02-28 |
2021-05-19 |
Seagen Inc. |
ANTI-TIGITE ANTIBODY
|
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
|
LT3618863T
(lt)
|
2017-05-01 |
2023-10-10 |
Agenus Inc. |
Anti-tigit antikūnai ir jų panaudojimo būdai
|
|
KR102770786B1
(ko)
|
2017-05-02 |
2025-02-20 |
머크 샤프 앤드 돔 엘엘씨 |
항-tigit 항체 단독의, 및 프로그램화된 사멸 수용체 1 (pd-1) 항체와 조합된 항-tigit 항체의 안정한 제제 및 그의 사용 방법
|
|
US20200299400A1
(en)
|
2017-05-25 |
2020-09-24 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
|
JP7348072B2
(ja)
|
2017-06-01 |
2023-09-20 |
コンピュジェン リミテッド |
三重併用抗体療法
|
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
WO2019023504A1
(en)
|
2017-07-27 |
2019-01-31 |
Iteos Therapeutics Sa |
ANTI-TIGIT ANTIBODIES
|
|
EP3664817A4
(en)
|
2017-08-07 |
2021-09-22 |
Phio Pharmaceuticals Corp. |
CHEMICALLY MODIFIED OLIGONUCLEOTIDES
|
|
JP7317272B2
(ja)
|
2017-09-29 |
2023-07-31 |
ジエンス ヘンルイ メデイシンカンパニー リミテッド |
Ｔｉｇｉｔ抗体、その抗原結合断片及びその医療用途 本願は、２０１９年９月２９日に出願された出願番号ｃｎ２０１７１０９０８５６５．３に基づいたものであり、その優先権を主張する。その開示は、その全体が参照により本明細書に組み込まれる。
|
|
US20210069241A1
(en)
|
2017-10-20 |
2021-03-11 |
Fred Hutchinson Cancer Research Center |
Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
|
|
JP2021502100A
(ja)
|
2017-11-08 |
2021-01-28 |
ゼンコア インコーポレイテッド |
新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
|
|
US20210106574A1
(en)
*
|
2017-12-27 |
2021-04-15 |
Tesaro, Inc. |
Methods of Treating Cancer
|
|
CN117050184A
(zh)
|
2017-12-28 |
2023-11-14 |
南京传奇生物科技有限公司 |
针对tigit的单域抗体和其变体
|
|
TWI877769B
(zh)
|
2017-12-30 |
2025-03-21 |
英屬開曼群島商百濟神州有限公司 |
抗tigit抗體及其作為治療和診斷的用途
|
|
AU2019207296A1
(en)
|
2018-01-15 |
2020-07-16 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies and variants thereof against TIGIT
|
|
EP3746119A4
(en)
|
2018-02-01 |
2021-11-10 |
Merck Sharp & Dohme Corp. |
METHOD OF TREATMENT FOR CANCER OR INFECTION USING A COMBINATION OF ANTI-PD-1 ANTIBODY, ANTI-LAG3 ANTIBODY, AND ANTI-TIGITE ANTIBODY
|
|
KR102224556B1
(ko)
|
2018-02-06 |
2021-03-09 |
아이-맵 바이오파마 유에스 리미티드 |
Ig 및 itim 도메인을 갖는 t 세포 면역 수용체 (tigit)에 대한 항체 및 이것의 사용
|
|
CN111836831A
(zh)
*
|
2018-02-26 |
2020-10-27 |
豪夫迈·罗氏有限公司 |
用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药
|
|
MX2020008795A
(es)
|
2018-02-28 |
2020-10-08 |
Yuhan Corp |
Anti cuerpos anti tigit y usos de los mismos.
|
|
CN118236374A
(zh)
|
2018-03-14 |
2024-06-25 |
奥瑞基尼肿瘤有限公司 |
使用1,2,4-噁二唑化合物调节tigit和pd-1信号传导途径的方法
|
|
TWI869346B
(zh)
*
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
KR20210016448A
(ko)
|
2018-06-01 |
2021-02-15 |
컴퓨젠 엘티디. |
항-pvrig/항-tigit 이중특이적 항체 및 사용 방법
|
|
WO2020020281A1
(zh)
|
2018-07-25 |
2020-01-30 |
信达生物制药(苏州)有限公司 |
抗tigit抗体及其用途
|
|
JP2021534196A
(ja)
|
2018-08-23 |
2021-12-09 |
シージェン インコーポレイテッド |
抗ｔｉｇｉｔ抗体
|
|
WO2020047329A1
(en)
|
2018-08-29 |
2020-03-05 |
Shattuck Labs, Inc. |
Chimeric proteins comprising extracellular domains and uses thereof
|
|
CN109384846B
(zh)
*
|
2018-09-25 |
2020-03-03 |
合肥瑞达免疫药物研究所有限公司 |
能够结合tigit的抗体或其抗原结合片段及用途
|
|
CA3118964A1
(en)
*
|
2018-11-05 |
2020-05-14 |
Merck Sharp & Dohme Corp. |
Dosing regimen of anti-tigit antibody for treatment of cancer
|
|
JP7491220B2
(ja)
*
|
2018-11-27 |
2024-05-28 |
小野薬品工業株式会社 |
免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療
|
|
EP3930851A4
(en)
|
2019-02-28 |
2023-03-29 |
Shattuck Labs, Inc. |
COMBINATION THERAPIES
|
|
CN109734806B
(zh)
|
2019-03-15 |
2022-07-01 |
安徽安科生物工程（集团）股份有限公司 |
一种全人源抗huTIGIT单克隆抗体及其应用
|
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
|
WO2021194481A1
(en)
*
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|